BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Savaliya BP, Shekouhi R, Mubarak F, Manaise HK, Jimenez PB, Kowkabany G, Popp RA, Popp K, Gabriel E. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors. World J Gastroenterol 2024; 30(24): 3052-3058 [PMID: 38983963 DOI: 10.3748/wjg.v30.i24.3052]
URL: https://www.wjgnet.com/1007-9327/full/v30/i24/3052.htm
Number Citing Articles
1
Occurrence of hepatitis B and C infection in pediatric patients with cancer at Alhadbaa Hospital in Mosul/IraqIraqi Journal of Cancer and Medical Genetics 2025; 18(2): 33 doi: 10.29409/20hcxw96
2
Yurou Jin, Chao Jin, Ronghui Xie, Jingming Zhang, Guangmin Wei, Ling Zheng. HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical managementFrontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1765054
3
Alla A. Kushch. Occult hepatitis B: prevalence and clinical significance. Role in liver pathology and in viral coinfectionsProblems of Virology 2025; 70(4): 299 doi: 10.36233/0507-4088-291